Oppenheimer Reiterates Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has reiterated an Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) but has lowered the price target from $74 to $73.
August 09, 2024 | 3:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer has reiterated an Outperform rating on Crinetics Pharmaceuticals but has slightly lowered the price target from $74 to $73.
The reiteration of the Outperform rating is positive, but the slight reduction in the price target may indicate some minor concerns or adjustments in valuation. Overall, the impact is neutral as the rating remains strong.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100